Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.

The oncologist - 5 Jul 2022

Wang Judy, Martin-Romano Patricia, Cassier Philippe, Johnson Melissa, Haura Eric, Lenox Laurie, Guo Yue, Bandyopadhyay Nibedita, Russell Michael, Shearin Elizabeth, Lauring Josh, Dahan Laetitia

Abstract excerpt

BACKGROUND: Patients with KRAS-mutant cancers have limited treatment options. Here we present a phase I study of JNJ-74699157, an oral, selective, covalent inhibitor of the KRAS G12C isoform, in patients with advanced cancer harboring the KRAS G12C mutation. METHODS: Eligible patients (aged ≥18 years) who had previously received or were ineligible for standard treatment received JNJ-74699157 once daily on a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35325211
DOI: 10.1093/oncolo/oyab080
PMCID: PMC9255981

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.PMID 35325211Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis.Semantic proximity Read ↗

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).Semantic proximity Read ↗

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.Semantic proximity Read ↗

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Semantic proximity Read ↗

Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.Semantic proximity Read ↗

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human StudySemantic proximity Read ↗

Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors.Semantic proximity Read ↗

Targeting the KRAS G12C mutation in patients with advanced solid tumors.Semantic proximity Read ↗

The Research Progress of Direct KRAS G12C Mutation Inhibitors.Semantic proximity Read ↗

143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.